stoxline Quote Chart Rank Option Currency Glossary
  
Antares Pharma, Inc. (ATRS)
5.59  0.01 (0.18%)    12-31 19:00
Open: 5.585
High: 5.59
Volume: 1,763,417
  
Pre. Close: 5.58
Low: 5.58
Market Cap: 0(M)
Technical analysis
2022-11-18 4:18:46 PM
Short term     
Mid term     
Targets 6-month :  6.52 1-year :  7.62
Resists First :  5.59 Second :  6.52
Pivot price 5.59
Supports First :  5.58 Second :  5.57
MAs MA(5) :  5.59 MA(20) :  5.59
MA(100) :  5.59 MA(250) :  4.81
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  100 D(3) :  100
RSI RSI(14): 78.6
52-week High :  5.59 Low :  3.1
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ATRS ] has closed Bollinger Bands are 0% narrower than normal.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.6 - 5.62 5.62 - 5.65
Low: 5.51 - 5.55 5.55 - 5.57
Close: 5.54 - 5.59 5.59 - 5.63
Company Description

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.

Headline News

Wed, 29 May 2024
Antares Pharma (ATRS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Movies UK

Tue, 24 May 2022
Halozyme Completes Antares Pharma Acquisition - PR Newswire

Tue, 19 Apr 2022
Halozyme Open to More Acquisitions After Antares Deal - GuruFocus.com

Wed, 13 Apr 2022
Halozyme bolsters drug delivery business with $960 mln Antares deal - Reuters

Wed, 13 Apr 2022
Halozyme acquires Antares Pharma for $960M to create drug delivery company - Drug Delivery Business News

Wed, 13 Apr 2022
Antares Pharma stock rockets after Halozyme buyout deal for a near-50% premium - MarketWatch

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Instruments & Supplies
Shares Out 171 (M)
Shares Float 134 (M)
Held by Insiders 7.5 (%)
Held by Institutions 62.8 (%)
Shares Short 4,780 (K)
Shares Short P.Month 3,910 (K)
Stock Financials
EPS 0.23
EPS Est Next Qtrly -0.03
EPS Est This Year -0.11
EPS Est Next Year 0
Book Value (p.s.) 1.02
Profit Margin 21.8 %
Operating Margin 10.4 %
Return on Assets (ttm) 5 %
Return on Equity (ttm) 26.6 %
Qtrly Rev. Growth -1.3 %
Gross Profit (p.s.) 0.67
Sales Per Share 1.07
EBITDA (p.s.) 0.13
Qtrly Earnings Growth 0 %
Operating Cash Flow 30 (M)
Levered Free Cash Flow -20 (M)
Stock Valuations
PE Ratio 24.3
PEG Ratio 0.8
Price to Book value 5.42
Price to Sales 5.2
Price to Cash Flow 32.09
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android